)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Mega Lifesciences
Mega Lifesciences (MEGA) investor relations material
Mega Lifesciences Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary1 Sep, 2026
Executive summary
Operating revenue for 1H26 grew 12.5% year-over-year, driven by double-digit growth in both branded products and distribution segments.
Gross margin improved to 52.0% from 50.5% in 1H25, reflecting stronger segmental performance.
EBITDA rose 33.8% year-over-year to THB 1,613mn, and reported net profit increased 33.1% to THB 1,119mn.
Adopted amendments to TAS 21 regarding foreign exchange rates, impacting assets and equity, especially due to Myanmar Kyat restrictions.
Acquired full control of Mega MSN Pte Ltd. in March 2026, consolidating its assets.
Financial highlights
Mega We Care™ segment revenue grew 11.9% year-over-year, with Southeast Asia contributing 73.3% of segment revenue.
Maxxcare™ distribution revenue increased 11.3% year-over-year, supported by improved conditions in Myanmar.
Segment results before tax for the six months ended 30 June 2026: Brands THB 1,403m, Distribution THB 241m, OEM THB 74m; total THB 1,719m, up from THB 1,552m year-over-year.
Consolidated net profit after tax for the six months: THB 1,119m, up from THB 841m year-over-year.
Total consolidated assets as of 30 June 2026: THB 16,026m, up from THB 15,759m at year-end 2025.
Outlook and guidance
Strategic plan targets doubling consolidated net profits by 2030 from the 2025 base year.
Healthy pipeline of nearly 100 products, with over 80 launched between 2022-25, expected to drive future sales.
Entry into Indonesia via manufacturing acquisition to contribute meaningfully from 2027.
Board approved interim dividend of THB 0.85 per share (THB 741.09m) to be paid in September 2026.
Planned THB 2.6bn investment in new manufacturing facilities in Vietnam, Myanmar, and Indonesia from 2026-2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Mega Lifesciences
- Flat FY23 revenue, higher adjusted profit and strong cash position support expansion plans.MEGA
Q4 2023 - Q1 2026 saw double-digit revenue and profit growth, driven by branded business strength.MEGAQ1 2026
- Branded business growth and improved margins offset revenue decline and higher tax impact.MEGAQ4 2025
- Nine-month revenue fell 10.3% YoY, but gross margin rose and cash flow remained strong.MEGAQ3 2025
- Revenue fell 14% YoY, but margin gains, expansion, and stable dividends support future growth.MEGAQ2 2025
- Net profit fell 9.6% to THB 1,373mn despite higher revenue and improved gross margin.MEGAQ3 2024
- Flat revenue and profit, stronger margins, branded growth, and Myanmar/forex headwinds.MEGAQ2 2024
- Stable profits and margin gains in FY24 set the stage for ambitious growth targets.MEGAQ4 2024
- Branded product growth and margin gains offset Myanmar-driven revenue drop in Q1 2025.MEGAQ1 2025
Next Mega Lifesciences earnings date
Q3 20261 Dec, 2026
Mega Lifesciences
Next Mega Lifesciences earnings date
Q3 20261 Dec, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Mega Lifesciences PCL is a company that specializes in the health and wellness sector, focusing on the manufacturing, marketing, selling, and distributing a wide range of products. These include quality pharmaceuticals, nutraceutical products, and fast-moving consumer goods (FMCG). Its offerings are designed to cater to a broad spectrum of health-related needs, emphasizing safe, effective, and world-class quality nutritional & herbal supplements, over-the-counter (OTC) products, and medications. The company operates through several key segments, including its Maxxcare distribution business, Mega We Care branded products business, and original equipment manufacturer (OEM) business. The Maxxcare division focuses on distributing various branded prescription pharmaceutical products, OTC, and FMCG products, offering services like warehouse management and assuming liability for bad debts. Mega We Care branded products business develops, manufactures, and markets its own brand of nutraceutical products, prescription pharmaceutical products, and OTC products. The company is headquartered in Bangkok, Thailand, and its shares are listed on the Stock Exchange of Thailand.